Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc

Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the 7MM.
DelveInsight's "Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Metastatic Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Triple Negative Breast Cancer Market Forecast [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Metastatic Triple Negative Breast Cancer Market Report:

*
The APAC Metastatic Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In June 2024, AstraZeneca faced a setback when its leading breast cancer treatment, Truqap (capivasertib), failed to show an improvement in overall survival (OS) in a Phase III trial for triple-negative breast cancer (TNBC). The combination of Truqap and chemotherapy (paclitaxel) in the Phase III CAPItello-290 trial did not meet its dual primary endpoints, which aimed to improve OS compared to chemotherapy and placebo, either in the overall trial population or in a subgroup of patients with tumors showing specific biomarker alterations (PIK3CA, AKT1, or PTEN).

*
In June 2024, G1 Therapeutics revealed the topline results from the final overall survival (OS) analysis of its Phase III PRESERVE 2 trial, which assessed the efficacy and safety of trilaciclib given before chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic triple-negative breast cancer (TNBC).

*
In February 2024, Carrick Therapeutics announced that the first patient has been administered the treatment in its Phase Ib/II clinical trial, which is evaluating the combination of samuraciclib (CT7001) in women with estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer.

*
In February 2024, Arvinas announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) as a monotherapy for treating adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer that has previously been treated with endocrine-based therapy.

*
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others

*
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others

*
The Metastatic Triple Negative Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Triple Negative Breast Cancer pipeline products will significantly revolutionize the Metastatic Triple Negative Breast Cancer market dynamics.

Metastatic Triple Negative Breast Cancer Overview

Metastatic Triple Negative Breast Cancer (mTNBC) is an aggressive and advanced form of breast cancer that is characterized by the absence of three key receptors - estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers, and when it progresses to the metastatic stage, it poses significant challenges in terms of treatment and prognosis.

Get a Free sample for the Metastatic Triple Negative Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast [https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Metastatic Triple Negative Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Triple Negative Breast Cancer Epidemiology Segmentation:

The Metastatic Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:

*
Total Prevalence of Metastatic Triple Negative Breast Cancer

*
Prevalent Cases of Metastatic Triple Negative Breast Cancer by severity

*
Gender-specific Prevalence of Metastatic Triple Negative Breast Cancer

*
Diagnosed Cases of Episodic and Chronic Metastatic Triple Negative Breast Cancer

Download the report to understand which factors are driving Metastatic Triple Negative Breast Cancer epidemiology trends @ Metastatic Triple Negative Breast Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Metastatic Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Triple Negative Breast Cancer Therapies and Key Companies

*
LY3023414: Eli Lilly and Company

*
Niraparib: Tesaro, Inc.

*
Pembrolizumab: Merck Sharp & Dohme LLC

*
Sacituzumab Govitecan: Gilead Sciences

*
NBE-002: NBE-Therapeutics AG

*
L-NMMA: Novartis Pharmaceuticals

*
Imprime PGG : HiberCell

*
TECENTRIQ: Hoffmann-La Roche

*
IPI-549: Infinity Pharmaceuticals

*
Leronlimab (PRO 140): CytoDyn

*
MDNA11: Medicenna Therapeutics

*
ASTX727: Astex Pharmaceuticals, Inc.

*
AG-01: A&G Pharmaceutical Inc.

*
ZEN003694: Zenith Epigenetics

*
AL101: Ayala Pharmaceuticals, Inc.

*
PMD-026: Phoenix Molecular Designs

*
CDX-1140: Celldex Therapeutics

Discover more about therapies set to grab major Metastatic Triple Negative Breast Cancer market share @ Metastatic Triple Negative Breast Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Metastatic Triple Negative Breast Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: APAC (India, China, South Korea, Taiwan, and Australia)

*
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others

*
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others

*
Metastatic Triple Negative Breast Cancer Therapeutic Assessment: Metastatic Triple Negative Breast Cancer current marketed and Metastatic Triple Negative Breast Cancer emerging therapies

*
Metastatic Triple Negative Breast Cancer Market Dynamics: Metastatic Triple Negative Breast Cancer market drivers and Metastatic Triple Negative Breast Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Metastatic Triple Negative Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Triple Negative Breast Cancer Market Access and Reimbursement

To know more about Metastatic Triple Negative Breast Cancer companies working in the treatment market, visit @ Metastatic Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Metastatic Triple Negative Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic Triple Negative Breast Cancer

3. SWOT analysis of Metastatic Triple Negative Breast Cancer

4. Metastatic Triple Negative Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic Triple Negative Breast Cancer Market Overview at a Glance

6. Metastatic Triple Negative Breast Cancer Disease Background and Overview

7. Metastatic Triple Negative Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Triple Negative Breast Cancer

9. Metastatic Triple Negative Breast Cancer Current Treatment and Medical Practices

10. Metastatic Triple Negative Breast Cancer Unmet Needs

11. Metastatic Triple Negative Breast Cancer Emerging Therapies

12. Metastatic Triple Negative Breast Cancer Market Outlook

13. Country-Wise Metastatic Triple Negative Breast Cancer Market Analysis (2020-2034)

14. Metastatic Triple Negative Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic Triple Negative Breast Cancer Market Drivers

16. Metastatic Triple Negative Breast Cancer Market Barriers

17. Metastatic Triple Negative Breast Cancer Appendix

18. Metastatic Triple Negative Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-triple-negative-breast-cancer-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-astrazeneca-bioeclipse-therapeutics-precigen-inc-clovis-oncology-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.